NCT02070796View on ClinicalTrials.gov

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Healthy

Interventions

DRUG

Rotigotine PR2.2.1

"Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."

DRUG

Rotigotine PR2.1.1

"Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."

Trial Locations (1)

Unknown

1, Hong Kong

All Listed Sponsors

lead

UCB Pharma SA

INDUSTRY

NCT02070796 - Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations | Biotech Hunter | Biotech Hunter